Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Gliosarcoma 2Glioma 2Glioblastoma 2Brain Neoplasms 2Medulloblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 4Irinotecan 3abemaciclib 2Radiotherapy 2Cyclophosphamide 2Bevacizumab 2palbociclib 1dostarlimab 1dinutuximab 1adavosertib 1Vorinostat 1Vincristine 1Valproic Acid 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiation 1Mebendazole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Eflornithine 1Carboplatin 1CLR1404 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × 1-methyltryptophan × Sarcoma × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡